Skip to content
Axcess News – Lifestyle
Author:
Nexla
Nexla Surpasses 1,000 Enterprise Connectors, Delivering the Connectivity, Context, and Governance AI Agents Need to Reach Production
July 28, 2026
Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
July 23, 2026
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
June 25, 2026
Zepbound (tirzepatide) and Shaquille O’Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
June 10, 2026
Nexla Launches MCP Studio to Build Governed, Task-Specific MCP Servers Across 600+ Enterprise Systems
June 9, 2026
Lilly’s oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
June 9, 2026
Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
June 8, 2026
Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
June 8, 2026
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association’s 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
May 28, 2026
Foundayo and Zepbound now covered for millions of Americans
May 28, 2026
1
2
Next Page
→